GAMMA Investing LLC Makes New $55,000 Investment in Insulet Co. (NASDAQ:PODD)

GAMMA Investing LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 252 shares of the medical instruments supplier’s stock, valued at approximately $55,000.

Other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust lifted its holdings in Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 123 shares during the last quarter. Allworth Financial LP raised its position in shares of Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 92 shares in the last quarter. Wolff Wiese Magana LLC lifted its stake in Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 134 shares during the last quarter. BluePath Capital Management LLC purchased a new stake in Insulet during the third quarter worth approximately $31,000. Finally, Lindbrook Capital LLC boosted its holdings in Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares in the last quarter.

Insulet Stock Down 1.0 %

PODD stock opened at $170.27 on Thursday. The stock has a market capitalization of $11.92 billion, a PE ratio of 58.51, a price-to-earnings-growth ratio of 3.07 and a beta of 0.98. The company has a fifty day moving average of $170.69 and a 200-day moving average of $180.53. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a one year low of $125.82 and a one year high of $335.91.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same quarter last year, the firm earned $0.55 earnings per share. The firm’s revenue was up 37.9% compared to the same quarter last year. As a group, analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. JPMorgan Chase & Co. raised their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Barclays reduced their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research note on Monday, February 26th. Finally, Piper Sandler lowered their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.